HD Biosciences owns PL2 in vitro labs in supporting our clients' anti-infective drug discoveries. The company provides services in varieties of anti-viral and anti-bacterial assays, plus target validation, HTS for hit identification to SAR lead optimization in both target-based and cell-based setup. We also offer anti-infective MOA research services, drug resistance studies, compound profiling etc. The clients could access our viral, bacterial strain banks that include standard lab adapted virus and bacterial strains, clinical isolates, ATCC QC

HDB enjoys excellent track records with the services to multinational and domestic pharmaceutical
companies. The quality of services that covers from sciences, logistics, project management, to data

•  Viruses: NL4-3, IIIB, clinical isolates

•  QC strains from ATCC, gram positive & gram negative

•  Lymphoid cell lines: MT2, MT4, SupT1, etc.

•  Bacterial strains from local hospitals, over 400 clinical isolates

•  Primary cells: PBMC, monocyte-macrophage cells

•  Bacterial strains from strains from North America

•  Strain validation by 16S RNA amplification & sequencing

•  Strain validation by biochemical test

•  Strain validation by Vitek2

•  Integrase assays; LEDGF HTRF assay; 3’ processing assay; Strand transfer

    assay; reverse transcriptase assay; capsid assay; fusion assay; CCR5

    specific compound screening

•  Drug resistant gene identification with multi-plex PCR & sequencing

•  Compound screening to identify hits for HCV subtype 1a,1b, 2a

•  Over 20 assays for anti-bacterial R&D, available for immediate use

•  Combination study to evaluate synergism ,antagonism of compounds

•  CLSI guidance for MIC/MBC testing

•  Evaluation & profiling of RNAi effect against HCV

•  NIH guidance for HTS and assay QC (plate uniformity, MSR, Z’, rank

    potency of reference compounds)

•  Identify resistant mutations & clone into the replicon

•  Profile compound against resistant replicons

Other assays : NS3 protease assay, etc.